Maternal administration of dexamethasone in severe pregnancy-induced hypertension
Autor: | Ernesto D. Ruvinsky, John C. Morrison, William E. Roberts, Phil Rhodes, James N. Martin, Sue M. Palmer, Stavros G. Douvas |
---|---|
Rok vydání: | 1984 |
Předmět: |
Risk
Pediatrics medicine.medical_specialty Neonatal respiratory distress syndrome Birth weight Pregnancy Complications Cardiovascular Dexamethasone Fetus Obstetric Labor Premature Fetal Organ Maturity Pregnancy medicine Humans Lung Respiratory Distress Syndrome Newborn Respiratory distress business.industry Infant Newborn Obstetrics and Gynecology Gestational age Amniotic Fluid medicine.disease Sphingomyelins Intraventricular hemorrhage Hypertension Phosphatidylcholines Female business medicine.drug |
Zdroj: | American Journal of Obstetrics and Gynecology. 149:722-726 |
ISSN: | 0002-9378 |
DOI: | 10.1016/0002-9378(84)90110-8 |
Popis: | Fourteen patients with severe pregnancy-induced hypertension and low lecithin/sphingomyelin (L/S) ratios were treated with 5 mg of dexamethasone phosphate intramuscularly every 12 hours for four doses to induce fetal pulmonary maturity. A comparison was made of the average gestational age, mean L/S ratio, method of delivery, Apgar scores, mean birth weight, and incidence of respiratory distress syndrome in these patients and in 16 patients with similar demographic backgrounds and clinical presentations who did not receive corticosteroid therapy. There was no significant difference between the two groups except that the time of treatment (or nontreatment) to delivery was longer in the steroid group. There were two cases of neonatal respiratory distress syndrome in the treatment group, and one of these infants died. In the control group, there were two neonatal deaths among four cases of respiratory distress syndrome. There was no clinical evidence of intraventricular hemorrhage in any neonate nor was there aggravation of hypertension in the parturient patients. The administration of corticosteroids to induce fetal pulmonary maturity in patients with severe pregnancy-induced hypertension who are carefully selected and monitored does not appear to be contraindicated. |
Databáze: | OpenAIRE |
Externí odkaz: |